Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
RSC Adv ; 10(41): 24705-24711, 2020 Jun 24.
Article in English | MEDLINE | ID: mdl-35516209

ABSTRACT

Spinel oxide NiCo2O4 supported on a three-dimensional hierarchically porous graphene-like carbon (3D HPG) material has been firstly used to enhance the activity of Pt for glycerol electrooxidation. The addition of NiCo2O4 into the Pt/HPG catalyst can significantly improve the catalytic performance for glycerol oxidation. When NiCo2O4 is added to the Pt/HPG catalyst, the onset potential is 25 mV more negative than that on the Pt/HPG catalyst without NiCo2O4. The current density at -0.3 V on the Pt-NiCo2O4 (wt 10 : 1)/HPG electrode is 1.3 times higher than that on the Pt (30 wt%)/HPG electrode. The Pt-NiCo2O4 electrode presented in this work shows great potential as an electrocatalyst for glycerol electrooxidation in an alkaline medium.

2.
Clin Neuropharmacol ; 43(1): 20-25, 2020.
Article in English | MEDLINE | ID: mdl-31738189

ABSTRACT

PURPOSE: This study aims to evaluate the effectiveness of levodopa as a therapeutic drug in the treatment of children and adults with amblyopia. METHODS: We performed a systematic review and meta-analysis with randomized controlled trials of levodopa and placebo in the treatment of amblyopia. All data were identified and extracted from the PubMed, EMBASE, Cochrane libraries, and the Chinese knowledge resource integration database. RESULTS: After screening the literature and evaluating the quality, 11 studies met the criteria from 308 studies. The mean difference of LogMAR visual acuity between levodopa and the placebo group was -0.1031 (95% confidence interval, -0.11 to -0.09; P < 0.0001). The improvement of visual acuities of the subgroup of younger patients with amblyopia was significantly higher than that of the placebo group (P < 0.0001). Increasing the dosage of levodopa and prolonging the treatment can significantly improve the curative effect. CONCLUSIONS: Levodopa is effective in the treatment of amblyopia by prolonging the treatment, especially for young patients.


Subject(s)
Amblyopia/drug therapy , Levodopa/therapeutic use , Visual Acuity/drug effects , Age Factors , Humans
SELECTION OF CITATIONS
SEARCH DETAIL